These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18223284)

  • 1. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
    Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Couriel D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE
    Haematologica; 2008 Feb; 93(2):257-64. PubMed ID: 18223284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
    Saini NY; Saliba RM; Rondon G; Maadani F; Popat U; Hosing CM; Oran B; Bashir Q; Olson A; Nieto Y; Alousi A; Kebriaei P; Srour S; Mehta R; Anderlini P; Shpall EJ; Qazilbash MH; Khouri IF; Fayad L; Lee H; Fowler N; Parmar S; Westin J; Hagemeister F; Champlin RE; Ciurea SO
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1340-1346. PubMed ID: 30763728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Canals C; Arranz R; Caballero D; Ribera JM; Brune M; Passweg J; Martino R; Valcárcel D; Besalduch J; Duarte R; León A; Pascual MJ; García-Noblejas A; López Corral L; Xicoy B; Sierra J; Schmitz N
    Haematologica; 2012 Feb; 97(2):310-7. PubMed ID: 21993674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
    O'Meara A; Halter J; Heim D; Gerull S; Bucher C; Passweg J; Buser A; Stern M
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):82-6. PubMed ID: 22897965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
    Ahmed S; Ghosh N; Ahn KW; Khanal M; Litovich C; Mussetti A; Chhabra S; Cairo M; Mei M; William B; Nathan S; Bejanyan N; Olsson RF; Dahi PB; van der Poel M; Steinberg A; Kanakry J; Cerny J; Farooq U; Seo S; Kharfan-Dabaja MA; Sureda A; Fenske TS; Hamadani M
    Br J Haematol; 2020 Aug; 190(4):573-582. PubMed ID: 32314807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
    Anderlini P; Saliba RM; Ledesma C; Plair T; Alousi AM; Hosing CM; Khouri IF; Nieto Y; Popat UR; Shpall EJ; Fanale MA; Hagemeister FB; Oki Y; Neelapu S; Romaguera JE; Younes A; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1333-1337. PubMed ID: 27064056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
    Craddock C; Jackson A; Loke J; Siddique S; Hodgkinson A; Mason J; Andrew G; Nagra S; Malladi R; Peniket A; Gilleece M; Salim R; Tholouli E; Potter V; Crawley C; Wheatley K; Protheroe R; Vyas P; Hunter A; Parker A; Wilson K; Pavlu J; Byrne J; Dillon R; Khan N; McCarthy N; Freeman SD
    J Clin Oncol; 2021 Mar; 39(7):768-778. PubMed ID: 33373276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
    Delioukina M; Zain J; Palmer JM; Tsai N; Thomas S; Forman S
    Bone Marrow Transplant; 2012 Jan; 47(1):65-72. PubMed ID: 21358679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
    Anderlini P; Saliba R; Acholonu S; Okoroji GJ; Donato M; Giralt S; Andersson B; Ueno NT; Khouri I; De Lima M; Hosing C; Cohen A; Ippoliti C; Romaguera J; Rodriguez MA; Pro B; Fayad L; Goy A; Younes A; Champlin RE
    Bone Marrow Transplant; 2005 May; 35(10):943-51. PubMed ID: 15806128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
    Majolino I; Davoli M; Carnevalli E; Locasciulli A; Di Bartolomeo P; Scimè R; Corradini P; Selleri C; Narni F; Musso M; Bregni M; Olivieri A; De Fabritiis P; Pogliani L; Arbelaez JE; Ruscio C; Bacigalupo A;
    Leuk Lymphoma; 2007 Apr; 48(4):759-66. PubMed ID: 17454635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.